Last updated: May 30, 2026
ORVATEN drug suppliers: who manufactures and supplies Orvaten (what to buy, from whom, and where it matters)
Orvaten is a branded pharmaceutical product marketed in multiple jurisdictions; supplier identification for “Orvaten” depends on the exact country, dosage form, and strength because the branded name can map to different active ingredients and local marketing authorizations. Without those specifics, it is not possible to produce a complete, accurate supplier list (manufacturers, MAH holders, wholesalers/distributors, contract manufacturing organizations, or API suppliers) tied to the correct Orvaten product.
What manufacturers supply Orvaten drug products in each country?
Featured answer: None provided. “Orvaten” supplier data is location- and formulation-specific; producing an accurate manufacturer/distributor list requires the jurisdiction-linked product identity.
How does Orvaten differ by dosage form and strength?
Local product labels determine the manufacturing authorization (marketing authorization holder), the finished dosage form manufacturer, and sometimes the packager. “Orvaten” may correspond to distinct formulations in different markets, which changes the supplier set.
What role do marketing authorization holders (MAHs) play in Orvaten supply?
The MAH controls quality system oversight and product release, often while the actual finished-dose manufacturing is performed by contract manufacturing organizations. Accurate supplier mapping requires the MAH and the finished-dose site listed for the specific authorized product.
How to find Orvaten suppliers using FDA Orange Book, EMA EPAR, and other registries?
Featured answer: None provided. Supplier identification from registries depends on locating the correct Orvaten entry in each regulator’s database, which requires the exact jurisdiction and active ingredient/formulation.
Orange Book listing approach (US)
The FDA Orange Book ties products to active ingredient(s), applicant/holder, listed patents, and NDA/ANDA details. Supplier mapping typically relies on label sections and manufacturing site listings that are not contained in the Orange Book patent tables.
EMA EPAR listing approach (EU)
EMA EPAR documents list MAH, manufacturing sites, and batch release arrangements. The EPAR must match the exact authorized formulation.
Local market product registries
National medicines agencies list MAH and manufacturer/packager sites. “Orvaten” branding can span multiple authorizations.
Which companies are the API suppliers for Orvaten?
Featured answer: None provided. API supplier identification requires confirmed active ingredient identity and a specific product authorization dossier. “Orvaten” alone is insufficient to determine API provenance.
What information sources typically reveal Orvaten API vendors
Common sources include supplier disclosure in regulatory dossiers, DMF holders for API manufacturing, and raw-material traceability in quality agreements. None can be reliably extracted without the correct product mapping.
What contract manufacturing organizations (CMOs) make Orvaten?
Featured answer: None provided. CMO identification requires the finished-dose manufacturing site listed for the exact Orvaten authorization and strength.
How finished-dose manufacturing sites affect supply reliability
Site-listed manufacturing affects batch release timelines, sterile versus non-sterile risk, packaging constraints, and regulatory inspection history. Accurate supply-chain assessment requires the exact manufacturing site and product form.
What wholesalers and distributors supply Orvaten in retail and hospital channels?
Featured answer: None provided. Distribution depends on each country’s channel structure and the local wholesaler network used by the MAH. Branding alone does not identify the distribution partners.
Hospital procurement and tender exposure
Tender documents and hospital formularies usually list the tender supplier, which can differ from the MAH and from the manufacturer.
How many suppliers exist for Orvaten and how concentrated is the supply chain?
Featured answer: None provided. Counting and concentration analysis requires a verified list of manufacturing sites, MAHs, and distributors by jurisdiction.
What patent or exclusivity status affects Orvaten supply and generic entry risk?
Featured answer: None provided. Patent and exclusivity analysis requires knowing the active ingredient, NDA/marketing authorization, and strength.
Key Takeaways
- “Orvaten” supplier identification cannot be completed accurately without the exact jurisdiction and the specific Orvaten product identity (active ingredient, dosage form, and strength).
- Supplier mapping must be tied to the correct marketing authorization entry to identify the MAH, finished-dose manufacturing sites, and distribution partners.
- API and CMO vendor lists also depend on the correct active ingredient and dossier-linked manufacturing authorizations.
FAQs
- How can I confirm the MAH for a specific Orvaten product in a target country?
- Do Orvaten formulations share the same CMO across dosage strengths within the same country?
- Which regulatory documents typically list finished-dose manufacturing and packaging sites for branded drugs like Orvaten?
- How do DMFs or CEPs help identify API suppliers behind a branded product named Orvaten?
- What changes in Orvaten supply occur after labeling updates or manufacturing site transfers?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
- EMA. European public assessment reports (EPAR) database.
- WHO. WHO Drug Information and international medicines registry references (as applicable).
